CD19 and primary central nervous system lymphoma: Herein, we reported the clinical efficacy and toxicities of 13 CNSL patients (four PCNSL and nine SCNSL) received sequential CD19/22 CAR T-cell immunotherapy following ASCT, no patient suffered grades 3-4 CRS, and only one patient experienced severe immune ICANS.